Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMed

Bushen Huatan formula improves reproductive and endocrine metabolic disorders in non-obese polycystic ovary syndrome rats via adipose tissue-derived exosomal miR-27a-3p/PPARG signaling pathway.

Chen M., Zhang R., Huang Y., Pan Y., Yang J., Huang Y.

Animal Study on Face & Skin, published in Gynecol Endocrinol (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Gynecol Endocrinol (2026)
Country
England
Reported sample size
—
Source database
PubMed
PMID
41954200
DOI
10.1080/09513590.2026.2655498

Abstract (original English)

This study aims to investigate the therapeutic effects of the Bushen Huatan (BSHT) Formula on non-obese polycystic ovary syndrome (PCOS) rats, and to explore its potential mechanisms of action. A PCOS model was induced in rats via letrozole, a high-fat/high-sucrose diet, and a PEPD inhibitor for 35 days; estrous cyclicity, fasting glucose, and glycated hemoglobin were monitored. After modeling, the animals underwent 28 days of assigned treatment, followed by an oral glucose tolerance test (OGTT) and assays for sex steroids and lipids. Ovarian and hepatic histology and hepatic steatosis were evaluated. Adipose-derived exosomes were characterized for size, concentration, and surface markers (TSG101, HSP70, CD63). Detect the expression levels of adipose tissue-derived exosomal microRNA-27a-3p (AT-EXO-miR-27a-3p) and ovarian Pparg mRNA. Ovarian PPARG, P-AKT, GLUT4, INSR and IRS-1 proteins were quantified. Compared with the model control group, BSHT lowered serum testosterone, elevated E₂ and FSH, ameliorated glucose intolerance, and improved lipid profiles by decreasing TC and TG and increasing HDL-C. Polycystic ovarian morphology and hepatic lipid accumulation were also attenuated. BSHT down-regulated AT-EXO-miR-27a-3p expression (mean ± SD: 5.13 ± 0.27 vs 17.91 ± 1.19; p < 0.001) and up-regulated both Pparg mRNA (0.38 ± 0.03 vs 0.08 ± 0.002; p < 0.001) and protein (0.37 ± 0.10 vs

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
AnimalsFemalePolycystic Ovary SyndromePPAR gammaMicroRNAsExosomesRatsSignal TransductionAdipose TissueDrugs, Chinese Herbal

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research